1. Home
  2. QSI vs OMER Comparison

QSI vs OMER Comparison

Compare QSI & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum-Si Incorporated

QSI

Quantum-Si Incorporated

HOLD

Current Price

$0.81

Market Cap

165.6M

Sector

Health Care

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$19.32

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QSI
OMER
Founded
2013
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.6M
844.6M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
QSI
OMER
Price
$0.81
$19.32
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$1.00
$32.50
AVG Volume (30 Days)
3.2M
2.3M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
28.17
98.15
EPS
N/A
0.77
Revenue
$2,436,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$618.07
$233.22
P/E Ratio
N/A
$23.66
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$3.94
52 Week High
$3.10
$19.65

Technical Indicators

Market Signals
Indicator
QSI
OMER
Relative Strength Index (RSI) 50.87 77.10
Support Level $0.70 $9.12
Resistance Level $1.06 N/A
Average True Range (ATR) 0.07 0.94
MACD 0.01 0.21
Stochastic Oscillator 44.80 96.85

Price Performance

Historical Comparison
QSI
OMER

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: